Practice parameter update

Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society

C. L. Harden, K. J. Meador, P. B. Pennell, W. A. Hauser, G. S. Gronseth, J. A. French, S. Wiebe, D. Thurman, B. S. Koppel, Peter W Kaplan, J. N. Robinson, J. Hopp, T. Y. Ting, B. Gidal, C. A. Hovinga, A. N. Wilner, B. Vazquez, L. Holmes, A. Krumholz, R. Finnell & 2 others D. Hirtz, C. Le Guen

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. METHODS: Systematic review of relevant articles published between January 1985 and June 2007. RESULTS: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of

Original languageEnglish (US)
Pages (from-to)133-141
Number of pages9
JournalNeurology
Volume73
Issue number2
DOIs
StatePublished - Jul 2009

Fingerprint

Teratogenesis
Biomedical Technology Assessment
Valproic Acid
Epilepsy
Pregnancy
Phenytoin
Apgar Score
Carbamazepine
First Pregnancy Trimester
Therapeutics
Phenobarbital
Combination Drug Therapy
Anticonvulsants
Gestational Age
Newborn Infant

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Practice parameter update : Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. / Harden, C. L.; Meador, K. J.; Pennell, P. B.; Hauser, W. A.; Gronseth, G. S.; French, J. A.; Wiebe, S.; Thurman, D.; Koppel, B. S.; Kaplan, Peter W; Robinson, J. N.; Hopp, J.; Ting, T. Y.; Gidal, B.; Hovinga, C. A.; Wilner, A. N.; Vazquez, B.; Holmes, L.; Krumholz, A.; Finnell, R.; Hirtz, D.; Le Guen, C.

In: Neurology, Vol. 73, No. 2, 07.2009, p. 133-141.

Research output: Contribution to journalArticle

Harden, CL, Meador, KJ, Pennell, PB, Hauser, WA, Gronseth, GS, French, JA, Wiebe, S, Thurman, D, Koppel, BS, Kaplan, PW, Robinson, JN, Hopp, J, Ting, TY, Gidal, B, Hovinga, CA, Wilner, AN, Vazquez, B, Holmes, L, Krumholz, A, Finnell, R, Hirtz, D & Le Guen, C 2009, 'Practice parameter update: Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society', Neurology, vol. 73, no. 2, pp. 133-141. https://doi.org/10.1212/WNL.0b013e3181a6b312
Harden, C. L. ; Meador, K. J. ; Pennell, P. B. ; Hauser, W. A. ; Gronseth, G. S. ; French, J. A. ; Wiebe, S. ; Thurman, D. ; Koppel, B. S. ; Kaplan, Peter W ; Robinson, J. N. ; Hopp, J. ; Ting, T. Y. ; Gidal, B. ; Hovinga, C. A. ; Wilner, A. N. ; Vazquez, B. ; Holmes, L. ; Krumholz, A. ; Finnell, R. ; Hirtz, D. ; Le Guen, C. / Practice parameter update : Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. In: Neurology. 2009 ; Vol. 73, No. 2. pp. 133-141.
@article{014047b722f343b7831f432faba90297,
title = "Practice parameter update: Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society",
abstract = "OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. METHODS: Systematic review of relevant articles published between January 1985 and June 2007. RESULTS: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of",
author = "Harden, {C. L.} and Meador, {K. J.} and Pennell, {P. B.} and Hauser, {W. A.} and Gronseth, {G. S.} and French, {J. A.} and S. Wiebe and D. Thurman and Koppel, {B. S.} and Kaplan, {Peter W} and Robinson, {J. N.} and J. Hopp and Ting, {T. Y.} and B. Gidal and Hovinga, {C. A.} and Wilner, {A. N.} and B. Vazquez and L. Holmes and A. Krumholz and R. Finnell and D. Hirtz and {Le Guen}, C.",
year = "2009",
month = "7",
doi = "10.1212/WNL.0b013e3181a6b312",
language = "English (US)",
volume = "73",
pages = "133--141",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Practice parameter update

T2 - Management issues for women with epilepsy - Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society

AU - Harden, C. L.

AU - Meador, K. J.

AU - Pennell, P. B.

AU - Hauser, W. A.

AU - Gronseth, G. S.

AU - French, J. A.

AU - Wiebe, S.

AU - Thurman, D.

AU - Koppel, B. S.

AU - Kaplan, Peter W

AU - Robinson, J. N.

AU - Hopp, J.

AU - Ting, T. Y.

AU - Gidal, B.

AU - Hovinga, C. A.

AU - Wilner, A. N.

AU - Vazquez, B.

AU - Holmes, L.

AU - Krumholz, A.

AU - Finnell, R.

AU - Hirtz, D.

AU - Le Guen, C.

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. METHODS: Systematic review of relevant articles published between January 1985 and June 2007. RESULTS: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of

AB - OBJECTIVE: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. METHODS: Systematic review of relevant articles published between January 1985 and June 2007. RESULTS: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of

UR - http://www.scopus.com/inward/record.url?scp=68149143987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149143987&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181a6b312

DO - 10.1212/WNL.0b013e3181a6b312

M3 - Article

VL - 73

SP - 133

EP - 141

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -